The 4,000-participant study will use a digital enrollment platform and will provide free genetic testing as well as support from doctors and genetics experts.
PGDx has the exclusive rights to develop both tissue- and blood-based diagnostics using MSK’s TMB-related intellectual property.
A Memorial Sloan Kettering Cancer Center-led team has followed more than 50 patients for more than two years after receiving immunotherapy, Time reports.
The analysis of HER2 and HER3 mutation carriers emphasizes how these studies can lead both to broadening and to narrowing of the patient populations for targeted drugs.
Some industry players are accusing CMS of advancing backdoor LDT regulation by proposing to cover NGS tests with FDA approval/clearance, except in a limited setting.
Researchers genotyped advanced cancer patients treated with immunotherapies and found that homozygosity at HLA loci was linked to decreased survival.
Memorial Sloan Kettering Cancer Center also hopes its partnership with analytics vendor Cota will help it prepare for value-based reimbursement.
The authorization implements regulatory strategies the FDA advanced with industry stakeholders, though labs may still be more inclined to take the CLIA route, as long as it is available.
The agency said that its action on MSK IMPACT "advances a policy framework that paves the way for the efficient review and availability of other NGS-based cancer profiling tools."
Analytics vendor Cota will classify records from Memorial Sloan Kettering in hopes of improving cancer care and research.
The Guardian reports that visa costs could prevent scientists and others from coming to the UK.
The Trump Administration is reconsidering its plan to issue an executive order to require federally funded research to be freely available upon publication, Times Higher Education reports.
Nature News says some preprint repositories may close down due to a lack of funds to cover costs.
In Nature this week: framework for analyzing cancer mutational signatures, treatment resistance in small cell lung cancer followed by increased intratumoral heterogeneity, and more.